#ProstateCancerCVDRisk


Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using U.S. administrative claims data
=============

<img src="https://img.shields.io/badge/Study%20Status-Started-blue.svg" alt="Study Status: Started">

- Analytics use case(s): **Estimation (Comparative Cohort), Characterization**
- Study type: **Clinical Research**
- Tags: **prostate cancer, castration-resistant prostate cancer, antiandrogens, aberaterone, enzalutamide, cardiovascular, safety, heart failure, acute myocardial infarction, ischemic stroke**
- Study lead: **Mitchell M. Conover**
- Study lead forums tag: **[[conovermitch]](https://forums.ohdsi.org/u/conovermitch)**
- Study start date: **11/27/2019**
- Study end date: **8/1/2021**
- Publications: **TBD**
- Results explorer: **-**

This repository contains study specification and documentation for a comparative cohort study comparing initiators aberaterone and enzalutamide with respect to incidence of various cardiovascular safety events including heart failure, acute myocardial infarction, and ischemic stroke.